Cuorips Inc.
Notice on Inclusion of Rehart® in Public Medical Insurance
The new drug Rehart® has been included in public medical insurance (date: 2026-09-01), with a covered reimbursement price of 53,200,000 yen and an applicable category of C2 (new function / new technology). The impact on future performance has already been incorporated into the full-year consolidated earnings forecast, and if amendments are needed, they will be disclosed promptly.
Key Figures
- Insurance coverage date: 2026 年９月１日
- Reimbursement price: 53,200,000 円
- Decision category: C２（new function / new technology）
AI要約
Rehart® inclusion in insurance coverage
The public medical insurance coverage for Rehart® has been formally decided, and the insurance coverage date has been disclosed as September 1, 2026. The decision category is C2 (new function / new technology), and the reimbursement price is 53,200,000 yen. Regarding the impact on future performance, it is stated that this has already been incorporated into the full-year consolidated earnings forecast published on July 28, 2026, and any further revision will be disclosed promptly if necessary.
Outlook and disclosure policy
The impact on performance is already incorporated into the full-year consolidated earnings forecast, and if revisions are needed, rapid disclosure will be made. At present, no additional figures are provided. Uncertainties include the effect of insurance coverage implementation and market introduction.
Quolips Corporation
Company overview · Stock price · Financial data · All IR
